Investment Thesis
AMN demonstrates fortress-like cash generation with exceptional free cash flow of $555.2M and 40.3% FCF margin, indicating an operationally efficient, asset-light healthcare staffing business. However, revenue declining 8.5% year-over-year presents a significant structural headwind that offsets financial strength, suggesting market contraction or competitive pressure requiring resolution before upgrading conviction.
Strengths
- Exceptional free cash flow generation ($555.2M) and 40.3% FCF margin demonstrates highly efficient, cash-accretive operations
- Strong cash position ($560.7M) and low capital intensity ($7.2M capex) provide substantial financial flexibility
- Effective shareholder returns with EPS growth of +35.6% despite flat net income, indicating disciplined capital allocation and buyback execution
Risks
- Significant revenue decline of -8.5% YoY indicates material market headwinds or competitive pressure in healthcare staffing sector
- Thin net profit margin of 4.5% leaves minimal buffer for margin compression or operational challenges
- Tight liquidity position (1.09x current ratio) and leverage above 1.0x (1.08x debt/equity) constrains financial flexibility amid revenue contraction
Key Metrics to Watch
- Revenue stabilization and path to return to growth
- Operating margin resilience and management of cost structure amid volume decline
- Free cash flow sustainability and capital allocation strategy (debt reduction vs. shareholder returns)
Financial Metrics
Revenue
1.4B
Net Income
62.2M
EPS (Diluted)
$1.59
Free Cash Flow
555.2M
Total Assets
2.6B
Cash
560.7M
Profitability Ratios
Gross Margin
26.8%
Operating Margin
8.5%
Net Margin
4.5%
ROE
8.7%
ROA
2.4%
FCF Margin
40.3%
Balance Sheet & Liquidity
Current Ratio
1.09x
Quick Ratio
1.09x
Debt/Equity
1.08x
Debt/Assets
72.6%
Interest Coverage
7.05x
Long-term Debt
767.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T09:27:03.492943 |
Data as of: 2026-03-31 |
Powered by Claude AI